Pioglitazone-d₄ (alkyl)

Cat. No.: HY-13956S1 Purity: 98.55%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Pioglitazone-d₄ (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1][2].

For research use only. We do not sell to patients.

Pioglitazone-d<sub>4</sub> (alkyl) Chemical Structure

Pioglitazone-d₄ (alkyl) Chemical Structure

CAS No. : 1134163-31-7

Size	Price	Stock	Quantity
1 mg	USD 980	In-stock	Estimated Time of Arrival: December 31
5 mg		Get quote
10 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Pioglitazone-d₄ (alkyl):

Pioglitazone In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

360.46

Formula

C₁₉H₁₆D₄N₂O₃S

CAS No.

1134163-31-7

Unlabeled CAS

111025-46-8

Appearance

Solid

Color

White to off-white

SMILES

C(C1C(=O)NC(=O)S1)C2=CC=C(OC(C(C3=CC=C(CC)C=N3)([2H])[2H])([2H])[2H])C=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (69.36 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7742 mL	13.8712 mL	27.7423 mL
5 mM	0.5548 mL	2.7742 mL	5.5485 mL
10 mM	0.2774 mL	1.3871 mL	2.7742 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.55%

Select Batch:

Data Sheet (272 KB) SDS (251 KB)

COA (246 KB)

Handling Instructions (2659 KB)

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

[2]. Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve [Content Brief]

[3]. Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. [Content Brief]

[4]. Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. [Content Brief]

[5]. Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7742 mL	13.8712 mL	27.7423 mL	69.3558 mL
	5 mM	0.5548 mL	2.7742 mL	5.5485 mL	13.8712 mL
	10 mM	0.2774 mL	1.3871 mL	2.7742 mL	6.9356 mL
	15 mM	0.1849 mL	0.9247 mL	1.8495 mL	4.6237 mL
	20 mM	0.1387 mL	0.6936 mL	1.3871 mL	3.4678 mL
	25 mM	0.1110 mL	0.5548 mL	1.1097 mL	2.7742 mL
	30 mM	0.0925 mL	0.4624 mL	0.9247 mL	2.3119 mL
	40 mM	0.0694 mL	0.3468 mL	0.6936 mL	1.7339 mL
	50 mM	0.0555 mL	0.2774 mL	0.5548 mL	1.3871 mL
	60 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1559 mL